Kenneth Candido, MD
Interventional Pain Medicine · Chicago, ILNPI 1518937937
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 27.3% of the total. Reporting peaked in 2021 at $5,467 and has fallen 86.1% since, to $763 in 2025.
Across 238 payments — averaging $63.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Ferring Pharmaceuticals Inc.$4K
- Lilly USA, LLC$4K
- Boston Scientific$644
- Biotronik NRO, Inc.$520
- Avanos Medical$472
- plus $2K from 23 others
Across 56 payments — averaging $8818.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Scilex Pharmaceuticals Inc.$232K
- Seikagaku Corporation$176K
- Abbott$65K
- Pfizer$21K
What the payments were for
- Consulting fees$7,08847%
- Travel & lodging$530%
- Food & beverage$8,06653%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 128 | $4,154 |
| Ferring Pharmaceuticals Inc. | 11 | $3,674 |
| Lilly USA, LLC | 1 | $3,600 |
| Boston Scientific | 14 | $644 |
| Biotronik NRO, Inc. | 8 | $520 |
| Avanos Medical | 6 | $472 |
| Si-bone, Inc. | 9 | $271 |
| Curonix LLC | 4 | $256 |
| Medtronic(2 entities) | 13 | $256 |
| SPR Therapeutics, Inc | 5 | $223 |
| Amgen | 15 | $223 |
| Stimwave Technologies Incorporated | 2 | $193 |
| Saluda Medical Americas, Inc. | 1 | $119 |
| Zavation Medical Products, LLC | 1 | $94 |
| Nevro Corp. | 3 | $90 |
| Collegium Pharmaceutical, Inc. | 3 | $87 |
| GRT US Holding, Inc. | 1 | $56 |
| Nalu Medical, Inc. | 1 | $49 |
| Mindray DS USA, Inc. | 1 | $33 |
| Vertiflex, Inc. | 2 | $30 |
| Globus Medical | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Valinor Pharma, LLC | 1 | $20 |
| Tolmar, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| USWM, LLC | 1 | $16 |
| Lenoss Medical Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,207 in reported general payments places this provider in the 85th percentile of 93 interventional pain medicine providers in Illinois.
See all interventional pain medicine providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 56 | $21,531 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 302 | $8,213 |
| Xtampza ErOxycodone Myristate | 11 | $6,225 |
| Hydromorphone ErHydromorphone Hcl | 28 | $5,702 |
| Hydromorphone Hcl | 80 | $2,325 |
| Gabapentin | 112 | $1,609 |
| Lidocaine | 14 | $1,268 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 16 | $679 |
| Morphine Sulfate ErMorphine Sulfate | 16 | $613 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $447 |
| Pregabalin | 16 | $363 |
| Cyclobenzaprine Hcl | 43 | $318 |
| Duloxetine Hcl | 16 | $217 |
| Morphine Sulfate | 12 | $197 |
| Tramadol Hcl | 34 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $87 | $6,22511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 interventional pain medicine providers in Illinois.
Other interventional pain medicine in Chicago
- Timothy LubenowChicago$556K
- Sandeep AminChicago$430K
- Matthew JaycoxChicago$123K
- Hong VoChicago$91K
- Asokumar BuvanendranChicago$52K
- Adam YoungChicago$29K
- Salman SagarwalaChicago$26K
- Sameer ShahChicago$10K
- James DiesfeldChicago$10K
- Xiaoyuam XieChicago$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.